LISCure Biosciences, a South Korea-based clinical-stage biopharmaceutical company, announced on Friday that it has received Fast Track designation from the US Food and Drug Administration (FDA) for LB-P8, its investigational drug for the treatment of primary sclerosing cholangitis (PSC).
PSC is a rare, chronic, cholestatic liver disease with significant unmet medical needs as there are no approved drugs available to treat it.
LB-P8 is undergoing assessment in a Phase 2 study in patients with PSC. According to LISCure, it is the only live biotherapeutic product currently reported to be in clinical development to address the requirement of individuals with PSC.
The company is carrying out a Phase 2 study in multiple sites across the US and Europe. Preliminary results are expected to be revealed in early 2025. Based on the results, the company says that it will make maximum use of accelerated programmes to bring LB-P8 to market as quickly as possible.
LB-P8 is also being developed for metabolic dysfunction-associated steatohepatitis (MASH).
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline